Bioton (BIO.WA) Stock Price

Bioton Price

GPW·CLOSED
3.82PLN+0.02 (+0.39 %)
Market closed

Over the last 19 years Bioton grew revenue by 1.4% annually, reaching 282.52 M PLN. Earnings per share have declined at 21.4% per year over the last 19 years. For Bioton, the net margin of 1.2% is broadly stable versus 1.8% a few years ago. The stock trades about 2% above its 52-week low.

Bioton stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Bioton over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Bioton stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Bioton's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Bioton Stock Price History
DateBioton Price
7/23/20263.82 PLN
7/22/20263.80 PLN
7/21/20263.86 PLN
7/20/20263.87 PLN
7/17/20263.82 PLN
7/16/20263.84 PLN
7/15/20263.83 PLN
7/14/20263.84 PLN
7/13/20263.82 PLN
7/10/20263.83 PLN
7/9/20263.85 PLN
7/8/20263.89 PLN
7/7/20263.95 PLN
7/6/20263.95 PLN
7/3/20263.96 PLN
7/2/20263.97 PLN
7/1/20263.96 PLN
6/30/20263.96 PLN
6/29/20263.97 PLN
6/26/20263.97 PLN
6/25/20263.90 PLN
6/24/20263.84 PLN
6/23/20263.85 PLN
6/22/20263.92 PLN
6/19/20263.99 PLN
6/18/20263.98 PLN
6/17/20263.98 PLN
6/16/20263.97 PLN
6/15/20263.98 PLN
6/12/20263.99 PLN
6/11/20264.00 PLN
6/10/20263.99 PLN
6/9/20264.05 PLN
6/8/20264.01 PLN
6/5/20264.06 PLN
6/3/20264.03 PLN
6/2/20264.03 PLN
6/1/20264.10 PLN
5/29/20264.18 PLN
5/28/20264.20 PLN
5/27/20264.15 PLN
5/26/20264.32 PLN
5/25/20264.34 PLN
5/22/20264.32 PLN
5/21/20264.32 PLN
5/20/20264.34 PLN
5/19/20264.31 PLN
5/18/20264.31 PLN
5/15/20264.36 PLN
5/14/20264.39 PLN
5/13/20264.29 PLN
5/12/20264.20 PLN
5/11/20264.19 PLN
5/8/20264.18 PLN
5/7/20264.20 PLN
5/6/20264.19 PLN
5/5/20264.15 PLN
5/4/20264.13 PLN
4/30/20264.17 PLN
4/29/20264.17 PLN
4/28/20264.17 PLN
4/27/20264.18 PLN
4/24/20264.18 PLN
4/23/20264.18 PLN
4/22/20264.20 PLN
4/21/20264.15 PLN
4/20/20264.16 PLN
4/17/20264.20 PLN
4/16/20264.22 PLN
4/15/20264.15 PLN
4/14/20264.19 PLN
4/13/20264.19 PLN
4/10/20264.19 PLN
4/9/20264.19 PLN
4/8/20264.16 PLN
4/7/20264.26 PLN
4/2/20264.30 PLN
4/1/20264.29 PLN
3/31/20264.32 PLN
3/30/20264.30 PLN
3/27/20264.30 PLN
3/26/20264.20 PLN
3/25/20264.23 PLN
3/24/20264.17 PLN
3/23/20264.24 PLN
3/20/20264.24 PLN
3/19/20264.15 PLN
3/18/20264.18 PLN
3/17/20264.09 PLN
3/16/20264.10 PLN
3/13/20264.12 PLN
3/12/20264.11 PLN
3/11/20264.12 PLN
3/10/20264.15 PLN
3/9/20264.09 PLN
3/6/20264.14 PLN
3/5/20264.10 PLN
3/4/20264.18 PLN
3/3/20264.14 PLN
3/2/20264.29 PLN
2/27/20264.35 PLN
2/26/20264.35 PLN
2/25/20264.32 PLN
2/24/20264.22 PLN
2/23/20264.38 PLN
2/20/20264.23 PLN
2/19/20264.18 PLN
2/18/20264.16 PLN
2/17/20264.17 PLN
2/16/20264.07 PLN
2/13/20264.10 PLN
2/12/20264.04 PLN
2/11/20264.02 PLN
2/10/20263.95 PLN
2/9/20263.95 PLN
2/6/20263.93 PLN
2/5/20263.95 PLN
2/4/20263.96 PLN
2/3/20263.99 PLN
2/2/20263.95 PLN
1/30/20263.97 PLN
1/29/20264.00 PLN
1/28/20264.02 PLN
1/27/20264.05 PLN
1/26/20264.02 PLN
1/23/20264.00 PLN
1/22/20264.07 PLN
1/21/20264.02 PLN
1/20/20264.00 PLN
1/19/20264.05 PLN
1/16/20264.07 PLN
1/15/20264.07 PLN
1/14/20264.00 PLN
1/13/20264.08 PLN
1/12/20264.00 PLN
1/9/20264.07 PLN
1/8/20264.07 PLN
1/7/20264.08 PLN
1/5/20264.00 PLN
1/2/20263.95 PLN
12/30/20253.86 PLN
12/29/20253.89 PLN
12/23/20253.76 PLN
12/22/20253.74 PLN
12/19/20253.78 PLN
12/18/20253.88 PLN
12/17/20253.89 PLN
12/16/20253.94 PLN
12/15/20253.95 PLN
12/12/20253.98 PLN
12/11/20254.00 PLN
12/10/20254.00 PLN
12/9/20254.00 PLN
12/8/20254.04 PLN
12/5/20254.00 PLN
12/4/20253.93 PLN
12/3/20254.00 PLN
12/2/20254.02 PLN
12/1/20254.00 PLN
11/28/20253.96 PLN
11/27/20253.93 PLN
11/26/20253.88 PLN
11/25/20253.93 PLN
11/24/20253.88 PLN
11/21/20253.90 PLN
11/20/20253.92 PLN
11/19/20253.99 PLN
11/18/20254.01 PLN
11/17/20254.15 PLN
11/14/20254.15 PLN
11/13/20254.19 PLN
11/12/20254.20 PLN
11/10/20254.21 PLN
11/7/20254.17 PLN
11/6/20254.26 PLN
11/5/20254.26 PLN
11/4/20254.27 PLN
11/3/20254.28 PLN
10/31/20254.28 PLN
10/30/20254.25 PLN
10/29/20254.25 PLN
10/28/20254.23 PLN
10/27/20254.27 PLN
10/24/20254.30 PLN
10/23/20254.29 PLN
10/22/20254.30 PLN
10/21/20254.22 PLN
10/20/20254.20 PLN
10/17/20254.25 PLN
10/16/20254.24 PLN
10/15/20254.25 PLN
10/14/20254.30 PLN
10/13/20254.30 PLN
10/10/20254.30 PLN
10/9/20254.32 PLN
10/8/20254.38 PLN
10/7/20254.39 PLN
10/6/20254.40 PLN
10/3/20254.41 PLN
10/2/20254.46 PLN
10/1/20254.40 PLN
9/30/20254.43 PLN
9/29/20254.48 PLN
9/26/20254.50 PLN
9/25/20254.55 PLN
9/24/20254.55 PLN
9/23/20254.50 PLN
9/22/20254.49 PLN
9/19/20254.50 PLN
9/18/20254.50 PLN
9/17/20254.49 PLN
9/16/20254.38 PLN
9/15/20254.34 PLN
9/12/20254.17 PLN
9/11/20254.17 PLN
9/10/20254.16 PLN
9/9/20254.17 PLN
9/8/20254.13 PLN
9/5/20254.19 PLN
9/4/20254.17 PLN
9/3/20254.16 PLN
9/2/20254.17 PLN
9/1/20254.17 PLN
8/29/20254.15 PLN
8/28/20254.17 PLN
8/27/20254.18 PLN
8/26/20254.23 PLN
8/25/20254.19 PLN
8/22/20254.18 PLN
8/21/20254.16 PLN
8/20/20254.16 PLN
8/19/20254.16 PLN
8/18/20254.12 PLN
8/14/20254.29 PLN
8/13/20254.45 PLN
8/12/20254.48 PLN
8/11/20254.48 PLN
8/8/20254.41 PLN
8/7/20254.48 PLN
8/6/20254.42 PLN
8/5/20254.44 PLN
8/4/20254.43 PLN
8/1/20254.50 PLN
7/31/20254.58 PLN
7/30/20254.65 PLN
7/29/20254.65 PLN
7/28/20254.40 PLN
7/25/20254.12 PLN
Access this data via the Eulerpool API
Get Free API Key

Bioton Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
241.17 M PLN
-50.52 M PLN
26.27 M PLN
Jan 1, 2019
202.03 M PLN
-71.22 M PLN
-126.69 M PLN
Jan 1, 2020
221.79 M PLN
30.24 M PLN
33.92 M PLN
Jan 1, 2021
163.03 M PLN
15.96 M PLN
2.88 M PLN
Jan 1, 2022
233.16 M PLN
27.93 M PLN
1.42 M PLN
Jan 1, 2023
181.64 M PLN
13.81 M PLN
2.28 M PLN
Jan 1, 2024
207.76 M PLN
-4.80 M PLN
-15.66 M PLN
Jan 1, 2025
282.52 M PLN
13.91 M PLN
3.39 M PLN

Bioton Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 24, 2026, 4:06 PM
 
REVENUEM PLN
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM PLN
EBITM PLN
EBIT MARGIN%
NET INCOMEM PLN
NET INCOME GROWTH%
SHARESM
2010201120122013201420152016201720182019202020212022202320242025
378.00289.00406.00340.00377.00332.00277.00361.00241.00202.00221.00163.00233.00181.00207.00282.00
32.17-23.5440.48-16.2610.88-11.94-16.5730.32-33.24-16.189.41-26.2442.94-22.3214.3636.23
56.0835.2952.4642.6541.9148.1949.8251.5248.1350.5047.0647.8540.7739.7830.9232.27
212.00102.00213.00145.00158.00160.00138.00186.00116.00102.00104.0078.0095.0072.0064.0091.00
48.00-54.0066.008.0021.0011.00-10.002.00-50.00-71.0030.0015.0027.0013.00-4.0013.00
12.70-18.6916.262.355.573.31-3.610.55-20.75-35.1513.579.2011.597.18-1.934.61
117.00-78.0037.00-6.003.00-522.00-28.00-20.0026.00-126.0033.002.001.002.00-15.003.00
-121.43-166.67-147.44-116.22-150.00-17,500.00-94.64-28.57-230.00-584.62-126.19-93.94-50.00100.00-850.00-120.00
53.2056.2071.5084.5085.8685.8685.8685.8685.8685.8685.8685.8685.8685.8685.8685.86
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Bioton generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Bioton retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Bioton's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Bioton has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Bioton's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Bioton stock margins

The Bioton margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bioton. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bioton.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
48.15 %
-20.95 %
10.89 %
Jan 1, 2019
50.65 %
-35.25 %
-62.71 %
Jan 1, 2020
47.24 %
13.63 %
15.29 %
Jan 1, 2021
48.06 %
9.79 %
1.77 %
Jan 1, 2022
41.07 %
11.98 %
0.61 %
Jan 1, 2023
40.11 %
7.61 %
1.25 %
Jan 1, 2024
31.21 %
-2.31 %
-7.54 %
Jan 1, 2025
32.49 %
4.92 %
1.20 %

Bioton Stock Revenue, EBIT, Earnings per Share

The Bioton earnings per share therefore indicates how much revenue Bioton has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
2.81 PLN
-0.59 PLN
0.31 PLN
Jan 1, 2019
2.35 PLN
-0.83 PLN
-1.48 PLN
Jan 1, 2020
2.58 PLN
0.35 PLN
0.40 PLN
Jan 1, 2021
1.90 PLN
0.19 PLN
0.03 PLN
Jan 1, 2022
2.72 PLN
0.33 PLN
0.02 PLN
Jan 1, 2023
2.12 PLN
0.16 PLN
0.03 PLN
Jan 1, 2024
2.42 PLN
-0.06 PLN
-0.18 PLN
Jan 1, 2025
3.29 PLN
0.16 PLN
0.04 PLN

Bioton business model & stock analysis

Bioton SA is a leading Polish biotechnology company specializing in the development of innovative drugs, diagnostics, and medical devices. The company was founded in 1989 and has since achieved remarkable success. Bioton is headquartered in Poland and employs approximately 1000 people worldwide. The company is listed on the Warsaw Stock Exchange and is supported by renowned investors. Business model Bioton operates various business divisions, including research and development, production, sales, as well as marketing and distribution. The company collaborates closely with leading academic institutions and research organizations and invests significant resources in the development of new groundbreaking technologies and products. The company's products and services are distributed and used in over 60 countries worldwide. Divisions Bioton is divided into three main business sectors, including biopharmaceuticals, diagnostics, and medical devices. Biopharmaceuticals Bioton is known for its biopharmaceuticals, particularly insulin and insulin analogs. Insulin is a hormone produced by the body to regulate blood sugar levels. Bioton offers various insulin products, including human insulin, insulin glargine, and insulin aspart. These products are approved for the treatment of diabetes mellitus and are distributed in over 50 countries worldwide. Diagnostics Bioton is also involved in the development and production of diagnostics. The company offers various testing systems for the diagnosis of infectious diseases, allergies, and autoimmune diseases. The product line also includes in vitro diagnostics that are used for medical therapy monitoring and disease detection. Medical devices Bioton also manufactures and distributes medical devices such as insulin pumps and blood glucose meters. These devices are designed for people with diabetes and assist in accurate insulin dosing and blood sugar level monitoring. Products In addition to insulin and insulin analogs, Bioton also produces a wide range of other drugs, including growth hormones, as well as follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These hormones are used for the treatment of infertility. Bioton is also involved in the development of novel technologies such as RNA interference (RNAi) and genomic research. The company invests significantly in innovative research projects aimed at the development of groundbreaking drugs and therapies. In conclusion, Bioton SA is a highly innovative biotechnology company with a wide range of products and a focus on research and development. The company operates in the global market and collaborates closely with renowned institutions and research organizations. Bioton's business model is based on the development of innovative technologies and products aimed at improving the quality of life for people worldwide.

Bioton SWOT Analysis

Strengths

Bioton SA has a strong market presence and brand recognition in the pharmaceutical industry. The company's extensive experience and expertise in the development and manufacturing of biotechnology and pharmaceutical products give it a competitive advantage. Additionally, Bioton SA has a diverse product portfolio, catering to various medical needs.

Weaknesses

One weakness of Bioton SA is its dependence on a limited number of key products. This exposes the company to market fluctuations and risks associated with product failures. Bioton SA may also face challenges in terms of intellectual property protection and maintaining a reliable supply chain.

Opportunities

There are several opportunities for Bioton SA to explore. The increasing global demand for biotechnology and pharmaceutical products presents a growth opportunity for the company. Bioton SA could also consider expanding its product offerings or entering new markets to diversify its revenue streams. Collaborations and partnerships with other industry players could further enhance Bioton SA's market position.

Threats

Bioton SA faces threats from intense competition in the pharmaceutical industry. The presence of both established multinational companies and emerging biotech firms can pose challenges to Bioton SA's market share. Additionally, regulatory changes and stringent compliance requirements may impact the company's operations and product development processes. Economic uncertainties and geopolitical factors can also influence Bioton SA's business environment.

Bioton Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Bioton historical P/E ratio, EBIT multiple, and P/S ratio

Bioton annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Bioton shares outstanding

The number of shares of Bioton was 85.86 M in 2025. This indicates how many shares Bioton is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
85.86 M Stocks
Jan 1, 2019
85.86 M Stocks
Jan 1, 2020
85.86 M Stocks
Jan 1, 2021
85.86 M Stocks
Jan 1, 2022
85.86 M Stocks
Jan 1, 2023
85.86 M Stocks
Jan 1, 2024
85.86 M Stocks
Jan 1, 2025
85.86 M Stocks

Bioton stock splits

In Bioton's history, there have been no stock splits.
Price targets and forecasts for Bioton are not yet available.

Bioton shareholder structure

% Name
31.64964%
Yifan Pharmaceutical Co Ltd
Yifan Pharmaceutical Co Ltd
7.16463%
Basolma Holding Ltd
Basolma Holding Ltd
6.00000%
Ais Investment 2 Sp. z.o.o.
Ais Investment 2 Sp. z.o.o.
5.03353%
Czarnik (Miroslaw)
Czarnik (Miroslaw)
5.00000%
Cui (Wenjun)
Cui (Wenjun)
0.25350%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.

Bioton Executives and Management Board

JL

Mr. Jeremy Launders

Chairman of the Management Board, Chief Executive Officer

Compensation1.82 M PLN
NC

Mr. Nicola Cadei

Chairman of the Supervisory Board · since 2019

Compensation39,000.00 PLN
RR

Mr. Ramesh Rajentheran

Vice Chairman of the Supervisory Board · since 2019

Compensation36,000.00 PLN
DT

Mr. Dariusz Trzeciak

Vice President of the Supervisory Board · since 2013

Compensation36,000.00 PLN
JL

Dr. Jubo Liu

Member of the Supervisory Board · since 2016

Compensation24,000.00 PLN

Frequently asked questions about Bioton

The business model of Bioton SA revolves around the development, manufacturing, and distribution of innovative biopharmaceutical products. Bioton SA specializes in the production of recombinant human insulin and insulin analogs, addressing the needs of diabetic patients worldwide. The company focuses on research and development activities to continuously improve their products and expand their portfolio. Bioton SA strives to provide high-quality and affordable healthcare solutions, catering to the growing demand for diabetes treatment options. With their strong commitment to innovation and patient care, Bioton SA aims to establish itself as a leading player in the biopharmaceutical industry.

All fundamentals and in-depth analysis of Bioton

Our stock analysis for Bioton stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bioton. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Bioton Stock
Bioton Revenue→
Bioton Stock
Bioton Net Income→
Bioton Stock
Bioton P/E→
Bioton Stock
Bioton P/S→
Bioton Stock
Bioton EBIT→
Bioton Stock
Bioton Dividend→
Bioton Stock
Bioton Directors Dealings→
Bioton Stock
Bioton Stocks→
Bioton Stock
Bioton Market capitalization→
Bioton Stock
Bioton Debt→
Bioton Stock
Bioton Liabilities→
Bioton Stock
Bioton Equity→
Bioton Stock
Bioton AAQS→
Bioton Stock
Bioton Employees→
Bioton Stock
Bioton ROE→
Bioton Stock
Bioton ROA→
Bioton Stock
Bioton ROCE→
Bioton Stock
Bioton News→
Bioton Stock
Bioton Analyst Price Targets→

Health Stocks

BioToxTech CoBiotequeBiotronBiotechnology AssetsBioventixBioteBioventusBiosynexBiovica InternationalBioSyentBioVieBiostem TechnologiesAll Stocks A–Z →